1. Does yellow fever 17D vaccine protect against melanoma?
- Author
-
Bernd Krone, Emanuela Fadda, E.G.E. de Vries, Alessandra Buja, Giuseppe Rausa, K.F. Koelmel, Giuseppe Mastrangelo, Jm Grange, and Public Health
- Subjects
Adult ,Male ,Adolescent ,Yellow fever vaccine ,Melanoma Yellow fever vaccine Cohort study Nested case-control study Cancer prevention ,Cohort Studies ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Antigen ,SDG 3 - Good Health and Well-being ,Medicine ,Humans ,Child ,Antigens, Viral ,Melanoma ,030304 developmental biology ,Vaccinia Vaccine ,Aged ,Aged, 80 and over ,0303 health sciences ,General Veterinary ,General Immunology and Microbiology ,business.industry ,Yellow fever ,Yellow Fever Vaccine ,Public Health, Environmental and Occupational Health ,Cancer ,Infant ,Middle Aged ,medicine.disease ,Virology ,3. Good health ,Vaccination ,Infectious Diseases ,030220 oncology & carcinogenesis ,Case-Control Studies ,Child, Preschool ,Immunology ,Molecular Medicine ,Female ,business ,BCG vaccine ,medicine.drug - Abstract
BCG vaccine, vaccinia vaccine and certain pathogens that were shown in previous studies to protect against melanoma have antigenic determinants homologous in their amino acids sequence with the melanoma antigen HERV-K-Mel, encoded by a human endogenous retrovirus K (HERV-K), which is expressed in about 95% of malignant melanocytes. Yellow fever vaccine (YFV) likewise contains an antigenic determinant with a close homology to HERV-K-MEL and might therefore also confer protection against Melanoma. To investigate this possibility we carried out a cohort study (28,306 subjects) and a nested case-control study (37 melamona cases and 151 tumors not expressing HERV-K-MEL) in Veneto region (North-Eastern Italy). The standardized incidence ratio was 1.33 (95% confidence interval, 0.84-2.11), 1.59 (0.97-2.59) and 0.59 while the age- gender-adjusted odds ratios were 1.00, 0.96 (0.43-2.14) and 0.26 (0.07-0.96), (0.19-1.84), at 0-4, 5-9, and >= 10 years elapsed from YFV administration, respectively. The risk of melanoma may therefore be lowered 10 years after vaccination with yellow fever vaccine. (C) 2008 Elsevier Ltd. All rights reserved.
- Published
- 2009
- Full Text
- View/download PDF